|
1
|
Karam H, Hurbain-Kosmath I and Housset B:
Antioxidant activity in alveolar epithelial type 2 cells of rats
during the development of bleomycin injury. Cell Biol Toxicol.
14:13–22. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Patel RB, Kotha SR, Sauers LA, Malireddy
S, Gurney TO, Gupta NN, Elton TS, Magalang UJ, Marsh CB, Haley BE,
et al: Thiol-redox antioxidants protect against lung vascular
endothelial cytoskeletal alterations caused by pulmonary fibrosis
inducer, bleomycin: Comparison between classical thiol-protectant,
N-acetyl-L-cysteine and novel thiol antioxidant,
N,N′-bis-2-mercaptoethyl isophthalamide. Toxicol Mech Methods.
22:383–396. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lazo JS and Chabner BA: Cancer
chemotherapy and biotherapy: principles and practice. Chabner BA
and Longo DL: Philadelphia: Lippincott-Raven; pp. 379–394. 1996
|
|
4
|
Hecht SM: Bleomycin: New perspectives on
the mechanism of action. J Nat Prod. 63:158–168. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chandler DB: Possible mechanisms of
bleomycin-induced fibrosis. Clin Chest Med. 11:21–30.
1990.PubMed/NCBI
|
|
6
|
Keane MP, Belperio JA, Arenberg DA,
Burdick MD, Xu ZJ, Xue YY and Strieter RM: IFN-gamma-inducible
protein-10 attenuates bleomycin-induced pulmonary fibrosis via
inhibition of angiogenesis. J Immunol. 163:5686–5692.
1999.PubMed/NCBI
|
|
7
|
Finkel T and Holbrook NJ: Oxidants,
oxidative stress and the biology of ageing. Nature. 408:239–247.
2000. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cross CE, Warren D, Gerriets JE, Wilson
DW, Halliwell B and Last JA: Deferoxamine injection does not affect
bleomycin induced lung fibrosis in rats. J Lab Clin Med.
106:433–438. 1985.PubMed/NCBI
|
|
9
|
Itoh K, Wakabayashi N, Katoh Y, Ishii T,
Igarashi K, Engel JD and Yamamoto M: Keap1 represses nuclear
activation of antioxidant responsive elements by Nrf2 through
binding to the amino-terminal Neh2 domain. Genes Dev. 13:76–86.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wasserman WW and Fahl WE: Functional
antioxidant responsive elements. Proc Natl Acad Sci USA.
94:5361–5366. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Itoh K, Chiba T, Takahashi S, Ishii T,
Igarashi K, Katoh Y, Oyake T, Hayashi N, Satoh K, Hatayama I, et
al: An Nrf2/small Maf heterodimer mediates the induction of phase
II detoxifying enzyme genes through antioxidant response elements.
Biochem Biophys Res Commun. 236:313–322. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kikuchi N, Ishii Y, Morishima Y, Yageta Y,
Haraguchi N, Itoh K, Yamamoto M and Hizawa N: Nrf2 protects against
pulmonary fibrosis by regulating the lung oxidant level and Th1/Th2
balance. Respir Res. 11:312010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mannava S, Zhuang D, Nair JR, Bansal R,
Wawrzyniak JA, Zucker SN, Fink EE, Moparthy KC, Hu Q, Liu S, et al:
KLF9 is a novel transcriptional regulator of bortezomib- and
LBH589-induced apoptosis in multiple myeloma cells. Blood.
119:1450–1458. 2012. View Article : Google Scholar :
|
|
14
|
Bradford MM: A rapid and sensitive method
for the quantitation of microgram quantities of protein utilizing
the principle of protein-dye binding. Anal Biochem. 72:248–254.
1976. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Serrano-Mollar A, Closa D, Prats N, Blesa
S, Martinez-Losa M, Cortijo J, Estrela JM, Morcillo EJ and Bulbena
O: In vivo antioxidant treatment protects against bleomycin-induced
lung damage in rats. Br J Pharmacol. 138:1037–1048. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mastruzzo C, Crimi N and Vancheri C: Role
of oxidative stress in pulmonary fi brosis. Monaldi Arch Chest Dis.
57:173–176. 2002.
|
|
17
|
Mata M, Ruiz A, Cerda M, Martinez-Losa M,
Cortijo J, Santangelo F, Serrano-Mollar A, Llombart-Bosch A and
Morcillo EJ: Oral N-acetylcysteine reduces bleomycininduced lung
damage and mucin Muc5ac expression in rats. Eur Respir J.
22:900–905. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cheresh P, Kim SJ, Tulasiram S and Kamp
DW: Oxidative stress and pulmonary fibrosis. Biochim Biophys Acta.
1832:1028–1040. 2013. View Article : Google Scholar :
|
|
19
|
Sayed-Ahmed MM, Mansour HH, Gharib OA and
Hafez HF: Acetyl-L-carnitine modulates bleomycin-induced oxidative
stress and energy depletion in lung tissues. J Egypt Natl Canc
Inst. 16:237–243. 2004.
|
|
20
|
Ali EN and Mansour SZ: Boswellic acids
extract attenuates pulmonary fi brosis induced by bleomycin and
oxidative stress from gamma irradiation in rats. Chin Med.
6:362011. View Article : Google Scholar
|
|
21
|
Iraz M, Erdogan H, Kotuk M, Yagmurca M,
Kilic T, Ermis H, Fadillioğlu E and Yildirim Z: Ginkgo biloba
inhibits bleo-mycin-induced lung fi brosis in rats. Pharmacol Res.
53:310–316. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Erdogan H, Fadillioglu E, Kotuk M, Iraz M,
Tasdemir S, Oztas Y and Yildirim Z: Effects of Ginkgo biloba on
plasma oxidant injury induced by bleomycin in rats. Toxicol Ind
Health. 22:47–52. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cho HY, Reddy SP, Yamamoto M and
Kleeberger SR: The transcription factor NRF2 protects against
pulmonary fibrosis. FASEB J. 18:1258–1260. 2004.PubMed/NCBI
|
|
24
|
Bieker JJ: Krüppel-like factors: Three
fingers in many pies. J Biol Chem. 276:34355–34358. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mouratis MA and Aidinis V: Modeling
pulmonary fibrosis with bleomycin. Curr Opin Pulm Med. 17:355–361.
2011. View Article : Google Scholar : PubMed/NCBI
|
